Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2024 | Comparing different assays for detecting AD plasma biomarkers

Gemma Salvadó • 20 Aug 2024
AAIC 2024
Alzheimer’s Disease Dementia

Gemma Salvadó, PhD, Lund University, Lund, Sweden, comments on the performance of different assays for detecting plasma biomarkers of Alzheimer’s disease (AD). She mentions studies showing that mass spectrometry-based methods perform better than immunoassays, although the difference is small. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2024 in Philadelphia, PA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Gemma Salvadó

The potential clinical utility of the novel p-tau205 biomarker in Alzheimer's disease
3:00
The potential clinical utility of the novel p-tau205 biomarker in Alzheimer's disease
Gemma Salvadó • 12 Dec 2025
The biological staging of AD using blood-based biomarkers: combining p-tau217 and MTBR-tau243
2:41
The biological staging of AD using blood-based biomarkers: combining p-tau217 and MTBR-tau243
Gemma Salvadó • 12 Dec 2025
The potential of plasma biomarkers in assessing preclinical Alzheimer's disease
3:25
The potential of plasma biomarkers in assessing preclinical Alzheimer's disease
Gemma Salvadó • 12 Dec 2025
Using plasma ptau217 to select cognitively unimpaired participants for AD prevention trials
4:34
Using plasma ptau217 to select cognitively unimpaired participants for AD prevention trials
Gemma Salvadó • 20 Aug 2024

Related Videos

A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
10:28
A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
Muhammad Umar Khan • 28 Aug 2026
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
3:25
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
Vikash Jaiswal • 26 Aug 2026
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
2:44
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
Jacqui Cannon • 5 Aug 2026
The Lewy Body Society's mission and impact
2:38
The Lewy Body Society's mission and impact
Jacqui Cannon • 5 Aug 2026

Choose your cookie settings

VJDementia uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJDementia is intended for healthcare professionals